|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF576 |
Gene summary for ZNF576 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF576 | Gene ID | 79177 |
| Gene name | zinc finger protein 576 | |
| Gene Alias | ZNF576 | |
| Cytomap | 19q13.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R0T0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79177 | ZNF576 | LP15 | Human | Oral cavity | LP | 2.14e-05 | 5.21e-01 | 0.2174 |
| 79177 | ZNF576 | SYSMH1 | Human | Oral cavity | OSCC | 1.19e-06 | 1.69e-01 | 0.1127 |
| 79177 | ZNF576 | SYSMH2 | Human | Oral cavity | OSCC | 4.81e-07 | 2.93e-01 | 0.2326 |
| 79177 | ZNF576 | SYSMH3 | Human | Oral cavity | OSCC | 1.90e-19 | 4.05e-01 | 0.2442 |
| 79177 | ZNF576 | SYSMH5 | Human | Oral cavity | OSCC | 8.44e-04 | 1.05e-01 | 0.0647 |
| 79177 | ZNF576 | SYSMH6 | Human | Oral cavity | OSCC | 2.61e-07 | 1.50e-01 | 0.1275 |
| 79177 | ZNF576 | male-WTA | Human | Thyroid | PTC | 2.96e-04 | 5.72e-02 | 0.1037 |
| 79177 | ZNF576 | PTC01 | Human | Thyroid | PTC | 2.58e-06 | 8.85e-02 | 0.1899 |
| 79177 | ZNF576 | PTC04 | Human | Thyroid | PTC | 1.61e-02 | 7.02e-02 | 0.1927 |
| 79177 | ZNF576 | PTC05 | Human | Thyroid | PTC | 7.47e-05 | 2.20e-01 | 0.2065 |
| 79177 | ZNF576 | PTC06 | Human | Thyroid | PTC | 1.22e-10 | 2.35e-01 | 0.2057 |
| 79177 | ZNF576 | PTC07 | Human | Thyroid | PTC | 1.13e-11 | 2.24e-01 | 0.2044 |
| 79177 | ZNF576 | ATC12 | Human | Thyroid | ATC | 6.26e-03 | 6.62e-02 | 0.34 |
| 79177 | ZNF576 | ATC13 | Human | Thyroid | ATC | 9.09e-50 | 8.22e-01 | 0.34 |
| 79177 | ZNF576 | ATC2 | Human | Thyroid | ATC | 3.86e-06 | 6.31e-01 | 0.34 |
| 79177 | ZNF576 | ATC4 | Human | Thyroid | ATC | 7.79e-04 | 1.35e-01 | 0.34 |
| 79177 | ZNF576 | ATC5 | Human | Thyroid | ATC | 1.75e-46 | 8.97e-01 | 0.34 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF576 | SNV | Missense_Mutation | c.180C>G | p.Asp60Glu | p.D60E | Q9H609 | protein_coding | tolerated(0.64) | benign(0.234) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| ZNF576 | SNV | Missense_Mutation | novel | c.44N>T | p.Ser15Leu | p.S15L | Q9H609 | protein_coding | deleterious_low_confidence(0.05) | benign(0.001) | TCGA-C5-A907-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ZNF576 | SNV | Missense_Mutation | c.202N>A | p.Gly68Arg | p.G68R | Q9H609 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF576 | SNV | Missense_Mutation | c.431N>T | p.Ala144Val | p.A144V | Q9H609 | protein_coding | tolerated(0.57) | benign(0.396) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF576 | SNV | Missense_Mutation | c.275N>A | p.Ser92Asn | p.S92N | Q9H609 | protein_coding | deleterious(0.03) | benign(0.247) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD | |
| ZNF576 | SNV | Missense_Mutation | c.271N>T | p.Arg91Cys | p.R91C | Q9H609 | protein_coding | deleterious(0.03) | benign(0.093) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF576 | SNV | Missense_Mutation | rs772352799 | c.229N>A | p.Ala77Thr | p.A77T | Q9H609 | protein_coding | tolerated(0.25) | possibly_damaging(0.598) | TCGA-A5-A0VO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF576 | SNV | Missense_Mutation | c.91N>A | p.Leu31Met | p.L31M | Q9H609 | protein_coding | tolerated(0.08) | possibly_damaging(0.467) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF576 | SNV | Missense_Mutation | c.230N>T | p.Ala77Val | p.A77V | Q9H609 | protein_coding | tolerated(0.07) | possibly_damaging(0.659) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF576 | SNV | Missense_Mutation | rs568418404 | c.152G>A | p.Arg51His | p.R51H | Q9H609 | protein_coding | tolerated(0.07) | probably_damaging(0.958) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |